Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Goserelin and tamoxifen after chemo benefits younger node-positive patients
April 19th, 2005
A regimen of goserelin and tamoxifen after chemotherapy benefits premenopausal women with nodepositive breast cancer, oncologists report. S. Deplacido and colleagues, University of Naples Federico II, wrote, "The sequential doxorubicin->CMF (CMF=cyclophosphamide, methotrexate, fluorouracil) regimen has never been compared to CMF in a randomized trial. The role of adding goserelin and tamoxifen (GT) after chemotherapy is unclear." They evaluated "the benefits of postchemotherapy GT in 466 premenopausal node-positive patients. The women were randomized to: (a) CMF x 6 cycles (CMF); (b) doxorubicin x 4 cycles...
Source: Cancer Weekly (2005-04-19)
|
